Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
On June 27, 2022, Fosun Pharmaceutical announced that it had successively reached cooperation with Amgen on the commercialization licensing of two innovative drugs of Amgen, namely, apmist tablets (trade name "otailar") and etkapide hydrochloride injection (trade name "parsabiv") in China (excluding Hong Kong, Macao and Taiwan). According to the announcement, Fosun Pharma USA, a subsidiary of Fosun Pharmaceutical Holdings, should pay up to US $47million down payment and regulatory milestones to Kai Pharma, a subsidiary of Amgen holdings, for the licensed products according to the agreement, and pay sales milestones according to the agreement.
This text is a result of machine translation.
Briefing Jun 28, 2022 04:29 PM
· Healthcare
Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
Briefing Jun 28, 2022 10:08 AM
· Healthcare
Yi Ming ang Ke delivers a statement to the main board of the Hong Kong stock exchange to develop a new generation of tumor immunotherapy
In-depth
Healthcare
WIM 2022: Transcript of Fireside Chat of Biotech [1/2]
EqualOcean organized the WIM2022 event in New York City from July 29 to July 30, 2022. The following is the transcript for Fireside Chat of Biotech. Leon Tang, Bing Yuan, Ying Huang, Dahai Guo, and Sally Wang are the five guest speakers in this chat.
Aug 05, 2022 09:11 PM
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Apr 18, 2022 06:30 PM
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Consumer Discretionary, Technology, Consumer StaplesTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
In-depth
Healthcare
WIM 2022: Transcript of Fireside Chat of Biotech [2/2]
EqualOcean organized the WIM2022 event in New York City from July 29 to July 30, 2022. The following is the transcript for Fireside Chat of Biotech. Leon Tang, Bing Yuan, Ying Huang, Dahai Guo, and Sally Wang are the five guest speakers in this chat.
Aug 05, 2022 09:08 PM
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
In-depth
Healthcare
AI in Medical Imaging in China: How to Switch from Adoption to more Sustainable Adoption
‘Artificial intelligence (AI) in medical imaging’ has been a hot term since 2015 in China. With many companies emerging, the adoption of AI-powered medical imaging has been spread widely. However, each coin has two sides. The AI-powered medical imaging industry is also facing several challenges. This article will first explain how AI has helped radiologists then move to how to switch to more sustainable adoption by tackling the challenges faced.
Jul 28, 2022 12:58 PM
In-depth
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Briefing Jun 23, 2022 10:20 AM
· Healthcare
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Briefing Jun 23, 2022 10:15 AM
· Healthcare
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Briefing Jun 23, 2022 10:06 AM
· Healthcare
Mojia biology announced the completion of round B financing
See more
Read next
Insight
In-depth
Insight
In-depth
Insight
In-depth